SCHEMBL770450

SCHEMBL770450

CCOc1ccc(-n2cnc3cc(NCc4ccc(C(C)C)cc4)ccc32)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.65
KDM4E B2RXH2 9/20 0.65
HPGD P15428 7/20 0.65
ALDH1A1 P00352 6/20 0.65
RAB9A P51151 9/20 0.63
NPC1 O15118 9/20 0.63
POLB P06746 1/20 0.63
GAA P10253 4/20 0.61
HSD17B10 Q99714 2/20 0.58
SMN1; SMN2 Q16637 4/20 0.53
TDP1 Q9NUW8 3/20 0.53
HTT P42858 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
MAPK1 P28482 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
KIT P10721 2/20 0.53
FLT3 P36888 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.52
LMNA P02545 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769960 0.92 RAB9A (0.61) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL769840 0.92 RAB9A (0.61) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL770154 0.91 RAB9A (0.64) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL769761 0.91 NPC1 (0.64) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL769029 0.89 RAB9A (0.68) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL770102 0.89 MAPT (0.70) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL770366 0.89 RAB9A (0.58) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL769848 0.89 MAPT (0.69) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL769915 0.88 RAB9A (0.61) MAPTKDM4EHPGDALDH1A1RAB9A
SCHEMBL769963 0.88 RAB9A (0.61) MAPTKDM4EHPGDALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US claimed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection ZC3HAV1, GZMB, GTF3C3 MAPT 2844/4885KDM4E 1661/4885HPGD 2757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.